Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial

BACKGROUND: Anticoagulation in patients with malignancy and atrial fibrillation is challenging because of enhanced risks for thrombosis and bleeding and the frequent need for invasive procedures. Data on direct oral antagonists in such patients are sparse. METHODS AND RESULTS: The ENGAGE AF‐TIMI 48...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Heart Assoc
Main Authors: Fanola, Christina L., Ruff, Christian T., Murphy, Sabina A., Jin, James, Duggal, Anil, Babilonia, Noe A., Sritara, Piyamitr, Mercuri, Michele F., Kamphuisen, Pieter W., Antman, Elliott M., Braunwald, Eugene, Giugliano, Robert P.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201390/
https://ncbi.nlm.nih.gov/pubmed/30369307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.118.008987
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados